Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics


Nymox Pharmaceutical Corporation (NYMX)

Today's Latest Price: $3.84 USD

0.11 (-2.78%)

Updated Jun 4 6:55pm

Add NYMX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NYMX Stock Summary

  • NYMX's price/sales ratio is 2,357.58; that's higher than the P/S ratio of 99.68% of US stocks.
  • With a year-over-year growth in debt of -84.21%, Nymox Pharmaceutical Corp's debt growth rate surpasses just 2.37% of about US stocks.
  • As for revenue growth, note that NYMX's revenue has grown -59.1% over the past 12 months; that beats the revenue growth of merely 2.83% of US companies in our set.
  • Stocks that are quantitatively similar to NYMX, based on their financial statements, market capitalization, and price volatility, are MRTX, CNCE, SCYX, ITCI, and TOCA.
  • NYMX's SEC filings can be seen here. And to visit Nymox Pharmaceutical Corp's official web site, go to www.nymox.com.
NYMX Daily Price Range
NYMX 52-Week Price Range

NYMX Stock Price Chart More Charts


NYMX Price/Volume Stats

Current price $3.84 52-week high $4.09
Prev. close $3.95 52-week low $1.32
Day low $3.78 Volume 164,200
Day high $3.95 Avg. volume 191,430
50-day MA $2.84 Dividend yield N/A
200-day MA $2.42 Market Cap 273.48M

Nymox Pharmaceutical Corporation (NYMX) Company Bio


Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.


NYMX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NYMX Latest Social Stream


Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

If You Had Bought Nymox Pharmaceutical (NASDAQ:NYMX) Shares Five Years Ago You'd Have Made 91%

It hasn't been the best quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shareholders, since the share price...

Yahoo | May 5, 2020

Nymox Announces Important New Patent Developments

HASBROUCK HEIGHTS, N.J., April 21, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international.

Yahoo | April 21, 2020

Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | March 21, 2020

Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology

Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer. This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment. The new publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection ‎Treatment of Grade Group 1 Prostate Cancer: Four Year Results”.

Yahoo | February 24, 2020

Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries. Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.

Yahoo | February 6, 2020

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo 21.52%
3-mo 42.22%
6-mo 104.26%
1-year 161.22%
3-year -4.95%
5-year 180.29%
YTD 74.55%
2019 67.94%
2018 -60.30%
2017 23.60%
2016 -18.60%
2015 720.00%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8613 seconds.